Assistant Professor of Pharmacology at the Medical College of Georgia via Emory Healthcare and UGA College of Pharmacy
Joined March 2019
- Tweets 46
- Following 256
- Followers 174
- Likes 674
Photos and videos
Daniel Anderson retweeted
Apr 21
Our @wikiguidelines letter to the editor regarding the controversy between IDSA and ATS on CAP guidelines is now published. Time for societies to modernize their approach to guidelines to STOP creating care standards based on opinions. @ABsteward @DrToddLee @AnilMakam @medrants
7
35
110
39,618
Daniel Anderson retweeted
5 Jun 2025
Your Role: Review existing guidelines across all specialties to evaluate whether or not recommendations are based on high-quality, adequately powered, peer-reviewed, and publicly accessible prospective studies, including at least one randomized controlled trial
1
3
6
2,476
Daniel Anderson retweeted
5 Jun 2025
📢📢📢Join our team appraising the level of evidence used to make consensus guideline recommendations across all specialties
Deadline to sign up: 6/20/25
New to WikiGuidelines?
Use the link below to complete WikiGuidelines New Participant application. forms.office.com/r/Tyb8R0iM8…
4
5
18
5,140
14 May 2025
Do empiric, adjunctive aminoglycosides improve outcomes in critically ill patients with GNR bloodstream infections? Not according to our propensity-matched observational cohort study!
14 May 2025
Check out our manuscript in @antibioticsmdpi #IDTwitter #MedEd 🦠💊🙏🏽
mdpi.com/2079-6382/14/5/497
@EudyJL @D_AndersonID @drdivsharma18 @MCG_AUG @mcg_id @WellstarHealth
1
3
130
5 Nov 2024
Excited to present our UTI @Wiki_Guidelines in @JAMANetworkOpen. It was an honor to work with so many brilliant clinicians and an organization whose charter I so strongly believe in.
4 Nov 2024
We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.
jamanetwork.com/searchresult…
2
8
469
Daniel Anderson retweeted
4 Nov 2024
This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap between the evidence and recommendation strength. ja.ma/3UBBW90 @bradspellberg
4
75
231
250,886
Daniel Anderson retweeted
4 Nov 2024
We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.
jamanetwork.com/searchresult…
37
69
24,948
18 Jun 2024
Congrats to @AU_UGAPharmRes former PGY1 Carly Loudermilk on her manuscript evaluating sequential PO therapy for E. Faecalis BSI. No difference in clinical outcomes and shorter hospital LOS in sequential PO. @UGAPharmacy @mcg_id @blandman19 @AndreaSikora journals.sagepub.com/doi/10.…
2
10
33
4,546
18 Jun 2024
IV-only patients were sicker at baseline (ICU admit but not CCI or Pitt) despite matching by source of infection. Median DOT ~2 weeks in both groups. PO patients received ~7 days of IV therapy. Was the second week of therapy necessary? @EudyJL
1
3
219
18 Jun 2024
Thanks to our amazing study team @strmltrofomonas @Pat_TuBROmycin @ViridansPharmD @SERGE_45_ABX and others
1
3
172
Daniel Anderson retweeted
🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold @IDpharmresearch and many @SIDPharm 🌟s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts #DOTS
link.springer.com/article/10…
3
45
120
25,638
13 Feb 2024
Is there an exception to #ShorterIsBetter for critically ill patients with Gram-negative BSI? Not according to our propensity-matched cohort study @EudyJL @drdivsharma18 @zsulaiman13 @ABsteward @mcg_id @AU_UGAPharmRes journals.sagepub.com/doi/10.…
2
16
36
6,375
5 May 2022
Thanks to the @UGAPharmacy students who make precepting such a joy! I’m humbled and honored to be recognized by this graduating class!
5 May 2022
Congratulations to the three outstanding preceptors selected to receive this year’s Preceptor of the Year Award:
- Dr. Daniel Anderson '18
- Dr. Amy Raufman Knauss '99
- Dr. Geneen Gibson
Thank you for the difference you make in the lives of our students every day!
2
27
Daniel Anderson retweeted
1 Apr 2022
I see you @ABC_PharmD! Double Antibiotic Coverage Does Not Improve Outcomes in Febrile Neutropenia
pharmacypracticenews.com/Cli…
2
5
28
29 Mar 2022
Thanks to @Contagion_Live for sharing our teams work on treating ESBL UTIs!
27 Mar 2022
Both noncarbapenem β-lactams and #carbapenems produced good outcomes in #UTI from β-lactamase-producing #Enterobacterales #IDTwitter
contagionlive.com/view/--lac…
1
2
Daniel Anderson retweeted
22 Feb 2022
🔥 NEW in OFID 🔥
👥 Retrospective cohort of admitted patients with ESBL UTI
💊 non-carbapenem beta-lactams (NCBLs) vs. carbapenems
Patients receiving NCBLs experienced:
☑️ no difference in LOS
☑️ higher rates of culture clearance
☑️ shorter DOTs
🔗 academic.oup.com/ofid/articl…
23
82
A new study in OFID suggests that carbapenems may not be necessary in the treatment of patients with urinary tract infections caused by ESBL-producing organisms.
📄: bit.ly/3JAmWA1
#IDSAJournals #OpenForumInfectDis @PaulSaxMD @DrJLi @D_AndersonID
10
78
255
Daniel Anderson retweeted
Congratulations🎉 to Dr. Daniel Anderson our Infectious Diseases/Internal Medicine pharmacist for his most recent publication! Way to go @D_AndersonID !! Follow the link below to read more. 🦠📰
5
33